Retatrutide dosing chart (mg to units)
PinPoint groups retatrutide under GLP-1 and describes a compound with GLP-1, GIP, and glucagon receptor activity. Its research-status field is Investigational. The chart draws on a 10 mg catalog vial and the five mg amounts present in the app's preset list.
Vial concentration
Water mL is treated as final solution mL in these columns.
| Vial contents | 1 mL water | 2 mL water | 3 mL water |
|---|---|---|---|
| 10 mg | 10 mg/mL10 U-100 units per mg | 5 mg/mL20 U-100 units per mg | 3.3333 mg/mL30 U-100 units per mg |
Vial source: PinPoint/Data/CompoundLibrary.swift, line 659, the Retatrutide entry. One documented amount is available.
Preset doses in PinPoint
Preset amounts are a conversion reference, not a personal dosing plan.
| Preset amount | 10 mg + 1 mL | 10 mg + 2 mL | 10 mg + 3 mL |
|---|---|---|---|
| 2 mg | 20 units | 40 units | 60 units |
| 4 mg | 40 units | 80 units | 120 unitsover one syringe |
| 6 mg | 60 units | 120 unitsover one syringe | 180 unitsover one syringe |
| 9 mg | 90 units | 180 unitsover one syringe | 270 unitsover one syringe |
| 12 mg | 120 unitsover one syringeexceeds vial contents | 240 unitsover one syringeexceeds vial contents | 360 unitsover one syringeexceeds vial contents |
Cited amounts
| Amount (mg) and source context | Frequency as stated | Route as stated | 10 mg + 1 mL | 10 mg + 2 mL | 10 mg + 3 mL | Source |
|---|---|---|---|---|---|---|
| 1 mg2023 adult phase 2 study; assigned study amount. | Once weekly | Subcutaneous | 10 units | 20 units | 30 units | Retatrutide phase 2 study, NEJM (2023)Peer-reviewed studyRetrieved 2026-10-05 |
| 2 mg2023 adult phase 2 study; initial escalation amount in several groups. | Once weekly | Subcutaneous | 20 units | 40 units | 60 units | Retatrutide phase 2 study, NEJM (2023)Peer-reviewed studyRetrieved 2026-10-05 |
| 4 mg2023 adult phase 2 study; assigned study amount; some groups began at 2 or 4 mg. | Once weekly | Subcutaneous | 40 units | 80 units | 120 unitsover one syringe | Retatrutide phase 2 study, NEJM (2023)Peer-reviewed studyRetrieved 2026-10-05 |
| 8 mg2023 adult phase 2 study; assigned study amount; some groups began at 2 or 4 mg. | Once weekly | Subcutaneous | 80 units | 160 unitsover one syringe | 240 unitsover one syringe | Retatrutide phase 2 study, NEJM (2023)Peer-reviewed studyRetrieved 2026-10-05 |
| 12 mg2023 adult phase 2 study; assigned 12 mg study amount; this group began at 2 mg. | Once weekly | Subcutaneous | 120 unitsover one syringeexceeds vial contents | 240 unitsover one syringeexceeds vial contents | 360 unitsover one syringeexceeds vial contents | Retatrutide phase 2 study, NEJM (2023)Peer-reviewed studyRetrieved 2026-10-05 |
How to read this chart
Find the concentration column. Divide the amount by that concentration. Multiply the mL value by 100 for U-100 units. Match the amount units before dividing.
units = dose ÷ (vial mg ÷ water mL) × 100
Amount and volume
One mg equals 1,000 mcg; 100 U-100 units equals 1 mL. Concentration connects amount to volume. Read the full conversion guide.
A six-day decay reference
The app's retatrutide half-life input is 144 hours, which converts to six days. Its common-frequency field reads Every 7 days. A week of logged events therefore spans a little more than one elimination half-life in the base model. Looking across consecutive weeks can show how several timestamped entries contribute to the estimated timeline. That is a time-based calculation using the record's stored parameters; the vial chart instead divides a fixed amount by a fixed liquid volume and does not depend on a log date.
Investigational parameters in a tracking record
For absorption, retatrutide's entry stores 0.80 as bioavailability and 24 hours as the time-to-peak input. The library points to a peer-reviewed human clinical reference and regards exact exposure values as estimates drawn from that study context. A one-day peak parameter and a six-day half-life describe different portions of the modeled curve: the rise after an entry and the subsequent elimination timescale. The Investigational label remains part of the compound's identity even though the arithmetic tables can display precise decimal volumes.
Keeping the app amounts intact
Retatrutide is recorded in mg, with subcutaneous as its route and compounded vial as its form. The stored presets are 2, 4, 6, 9, and 12 mg. They do not form equal increments, so the chart uses those five values directly rather than filling in intermediate rows. The last amount is 120% of the documented 10 mg vial. Its contents flag is independent of the water column: adding a larger liquid volume changes concentration but leaves that 12-to-10 amount comparison unchanged.
Catalog amount, three concentrations
The vial citation is a supplier catalog specifying 10 mg per retatrutide vial. Dividing that amount into 1, 2, or 3 mL produces the three concentration columns. For the 6 mg preset, the fraction of the vial is 0.6. It occupies 0.6 mL in the first column and 1.8 mL in the third, giving 60 and 180 U-100 units respectively. The over-one-syringe marker appears in the latter case because the calculated volume exceeds the chart's one-milliliter capacity reference.
Questions about the conversion
What concentration is Retatrutide at 10 mg in 1 mL?
10 mg divided by 1 mL is 10 mg per mL. That volume spans 100 U-100 syringe units.
How does 2 mL change the concentration of this Retatrutide vial?
10 mg divided by 2 mL is 5 mg per mL, half the concentration in the 1 mL column.
What does the 3 mL column mean for Retatrutide?
10 mg divided by 3 mL is approximately 3.3333 mg per mL. The full 3 mL volume corresponds to 300 U-100 units.
How many units is 2 mg of Retatrutide from this vial in 2 mL?
2 mg divided by 5 mg per mL is 0.4 mL, or 40 U-100 units.
How many units is the 1 mg cited amount of Retatrutide from a 10 mg vial in 2 mL?
The arithmetic is 1 mg ÷ 5 mg/mL × 100 = 20 U-100 units (0.2 mL). The amount is cited in Retatrutide phase 2 study, NEJM (2023). 2023 adult phase 2 study; assigned study amount.
Track your calculations in the app
PinPoint for iOS brings vial setup, unit conversion, dose logs, site rotation, and protocol tracking together. Enter vial size and water volume for concentration and syringe units, then log injections with compound, dose, site, and pain level.
Get PinPoint on the App Store